Humana Inc. (NYSE:HUM) Shares Acquired by SVB Wealth LLC

SVB Wealth LLC boosted its position in Humana Inc. (NYSE:HUM) by 10.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,475 shares of the insurance provider’s stock after purchasing an additional 139 shares during the quarter. SVB Wealth LLC’s holdings in Humana were worth $675,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cibc World Market Inc. raised its stake in shares of Humana by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 5,709 shares of the insurance provider’s stock worth $2,484,000 after buying an additional 217 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Humana by 0.6% during the 1st quarter. Blair William & Co. IL now owns 5,660 shares of the insurance provider’s stock valued at $2,463,000 after purchasing an additional 32 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of Humana by 0.5% in the 1st quarter. Cetera Investment Advisers now owns 4,906 shares of the insurance provider’s stock worth $2,135,000 after purchasing an additional 26 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Humana by 19.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 615 shares of the insurance provider’s stock worth $268,000 after purchasing an additional 98 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its stake in Humana by 25.0% during the first quarter. Candriam Luxembourg S.C.A. now owns 29,809 shares of the insurance provider’s stock valued at $12,971,000 after purchasing an additional 5,964 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Insider Activity at Humana

In other news, Director Jorge S. Mesquita acquired 545 shares of Humana stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares in the company, valued at $946,358.02. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.32% of the company’s stock.

Humana Price Performance

Shares of NYSE:HUM opened at $328.33 on Friday. The firm has a market cap of $39.61 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 1.90 and a beta of 0.45. Humana Inc. has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $330.40 and a 200 day simple moving average of $400.99.

Humana (NYSE:HUM) last released its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The firm had revenue of $26.46 billion for the quarter, compared to analyst estimates of $25.47 billion. Humana had a net margin of 2.34% and a return on equity of 19.44%. Humana’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.62 EPS. As a group, sell-side analysts predict that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.08%. Humana’s payout ratio is 17.86%.

Analyst Ratings Changes

HUM has been the topic of several recent research reports. StockNews.com lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Argus lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $391.00 price target on shares of Humana in a research report on Wednesday, April 10th. Raymond James initiated coverage on shares of Humana in a research report on Friday, March 22nd. They issued a “market perform” rating on the stock. Finally, Bank of America restated a “neutral” rating and issued a $342.00 price target (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $465.42.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.